|
1 |
Impact of TP53 mutation status in elderly AML patients when adding all‐trans retinoic acid or valproic acid to decitabine
Bresser, Helena. - Augsburg : Universität Augsburg, 2025
|
|
|
|
2 |
Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients over 60 years of age: a prospective phase II study
Kröger, Nicolaus. - Augsburg : Universität Augsburg, 2023
|
|
|
|
3 |
Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q
Panagiota, Victoria. - Leipzig : Universitätsbibliothek Leipzig, 2023
|
|
|
|
4 |
Reduced 8-Gray compared to standard 12-Gray Total Body Irradiation for allogeneic transplantation in first remission acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of the EBMT
Spyridonidis, Alexandros. - Augsburg : Universität Augsburg, 2023
|
|
|
5 |
Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation
Enthalten in Bone marrow transplantation 17.11.2023: 1-7
|
|
|
|
6 |
Evolution of severe (transfusion-dependent) anaemia in myelodysplastic syndromes with 5q deletion is characterized by a macrophage-associated failure of the eythropoietic niche
Buesche, Guntram. - Aachen : Universitätsbibliothek der RWTH Aachen, 2022
|
|
|
|
7 |
Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results
Rücker, Frank Gert. - Ulm : Universität Ulm, 2021
|
|
|
|
8 |
A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapy
Mischak-Weissinger, Eva Maria. - Augsburg : Universität Augsburg, 2020
|
|
|
|
9 |
Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia
Schmaelter, Ann-Kristin. - Augsburg : Universität Augsburg, 2020
|
|
|
|
10 |
18F-FDG PET/CT of off-target lymphoid organs in CD19-targeting chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma
Enthalten in Annals of nuclear medicine 11.11.2020: 1-7
|
|
Administration
